Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: Characterization of new CB 1 cannabinoid receptor inverse agonists/antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 872-882

  Muccioli, Giulio G ^a   Wouters, Johan ^b   Charlier, Caroline ^b   Scriba, Gerhard K E ^c   Pizza, Teresa ^a   Di Pace, Pierluigi ^a   De Martino, Paolo ^a   Poppitz, Wolfgang ^c   Poupaert, Jacques H ^a   Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(4 BROMOPHENYL) 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 1,3 BIS(4 CHLOROPHENYL) 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 1,3,5 TRIPHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE DERIVATIVE; 1,3,5 TRIPHENYLIMIDAZOLIDINE 2,4 DIONE DERIVATIVE; ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR INVERSE AGONIST; CANNABINOID 1 RECEPTOR INVERSE ANTAGONIST; CANNABINOID RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYDANTOIN DERIVATIVE; NICOTINE; OPIATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; METABOLIC SYNDROME X; MOLECULAR MODEL; NONHUMAN; OBESITY; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMIDAZOLIDINES; IMIDAZOLINES; MALE; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32344434497     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050484f     Document Type: Article

References (46)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a Cannabinoid Receptor and Functionnal Expression of the Cloned cDNA. Nature 1990, 346, 561-564.
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61-65.
3. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
4. Mechoulam, R.; Ben-Shabal, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almong, S.; Martin, B. R.; Complon, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, that Binds to Cannabinoid Receptors. Biochem. Pharmacol. 1995, 50, 83-90.
5. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
6. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme That Degrades Neuromodulatory Fatty-Acid Amides. Nature 1996, 384, 83-87.
7. Karlsson, M.; Contreras, J. A.; Hellman, U.; Tornqvist, H.; Holm, C. cDNA Cloning. Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase. Evolutionary Relationship To Esterases, Lysophospholipases, And Haloperoxidases. J. Biol. Chem. 1997, 272, 27218-27223.
8. Tsuboi, K.; Sun, Y. X.; Okamoto, Y.; Araki, N.; Tonai, T.; Ueda, N. Molecular Characterization of N-Acylethanolamine-Hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase. J. Biol. Chem. 2005, 280, 11082-11092.
9. Lambert, D. M.; Fowler, C. J. The Endocannabinoid System: Drug Targets, Lead Compounds and Potential Therapeutic Applications. J. Med. Chem. 2005, 48, 5059-5087.
10. Notcutt, W.; Price, M.; Miller, R.; Newport, S.; Phillips, C.; Simmons, S.; Sansom, C. Initial Experiences with Medicinal Extracts of Cannabis for Chronic Pain: Results from 34 'N of 1' studies. Anaesthesia 2004, 59, 440-52.
11. Muller-Vahl, K. R.; Schneider, U.; Prevedel, H.; Theloe, K.; Kolbe, H.; Daldrup, T.; Emrich, H. M. Delta 9-Tetrahydrocannabinol (THC) Is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial. J. Clin. Psychiatry 2003, 64, 459-465.
12. Zajicek, J.; Fox, P.; Sanders, H.; Wright, D.; Vickery, J.; Nunn, A.; Thompson, A. Cannabinoids for Treatment of Spasticity and Other Symptoms Related to Multiple Sclerosis (CAMS Study): Multicentre Randomised Placebo-Controlled Trial. Lancet 2003, 362, 1517-1526.
13. 1 Cannabinoid Receptor Antagonists. Curr. Opin. Drug Discov. Devel. 2004, 7, 498-506.
14. 1 Cannabinoid Receptor Antagonists. Drug Discovery Today 2005, 10, 693-702.
15. 1 Antagonists. Idrugs 2005, 8, 53-66.
16. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D. SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor. FEBS Lett. 1994, 350, 240-244.
17. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rössner, S.; for the RIO-Europe Study Group. Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience from the RIO-Europe Study. Lancet 2005, 365, 1389-1397.
18. Cleland, J. G. F.; Ghosh, J.; Freemantle, N.; Kaye, G. C.; Nasir, M.; Clark, A. L.; Coletta, A. P. Clinical Trials Update and Cumulative Meta-Analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and Cardiac Resynchronisation Therapy in Heart Failure. Eur. J. Heart Fail. 2005, 6, 501-508.
19. 1 Receptor Antagonists as Promising New Medications for Drug Dependence. J. Pharm. Exp. Ther. 2005, 312, 875-883.
20. 1 Cannabinoid Receptor Blockade Is Protective During Transient, Focal Cerebral Ischemia. Neuroscience 2004, 129, 743-750.
21. Muccioli, G. G.; Lambert, D. M. Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors. Curr. Med. Chem. 2005, 12, 1361-1394.
22. 1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization. J. Pharmacol. Exp. Ther. 2004, 310, 905-914.
23. Jagerovic, N.; Hernandez-Folgado, L.; Alkorta, I.; Goya, P.; Navarro, M.; Serrano, A.; Rodriguez de Fonseca, F.; Dannert, M. T.; Alsasua, A.; Suardiaz, M.; Pascual, D.; Martin, M. I. Discovery of 5-(4-Chlorophenyl)-1-(2,4- dichlorophenyl)-3-hexyl-1H-1,2.4-triazole. a Novel in Vivo Cannabinoid Antagonist Containing a 1,2,4-Triazole Motif. J. Med. Chem. 2004, 47, 2939-2942.
24. 1 Cannabinoid Receptor Antagonists. J. Med. Chem. 2005, 48, 1823-1838.
25. 1 Cannabinoid Receptor Antagonists. J. Med. Chem. 2004, 47, 627-643.
26. 1 Receptor Inverse Agonists. Bioorg. Med. Chem. Lett. 2005, 15, 1441-1446.
27. 1 Inverse Agonists. Bioorg. Med. Chem. Lett. 2005, 15, 645-651.
28. Kanyonyo, M.; Govaerts, S. J.; Hermans, E.; Poupaert, J. H.; Lambert, D. M. 3-Alkyl-(5,5′-diphenyl)imidazolidinediones as New Cannabinoid Receptor Ligands. Bioorg. Med. Chem. Lett. 1999, 9, 2233-2236.
29. Muccioli, G. G.; Poupaert, J. H.; Wouters, J.; Norberg, B.; Poppitz, W.; Scriba, G. K. E.; Lambert, D. M. A Rapid and Efficient Microwave-Assisted Synthesis of Hydantoins and Thiohydantoins. Tetrahedron 2003, 59, 1301-1307.
30. 1 Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling. J. Med. Chem. 2002, 45, 1748-1756.
31. 1 Cannabinoid Receptor Ligands: Synthesis and Pharmacological Evaluation. J. Med. Chem. 2005, 48, 2509-2516.
32. Riley, H. A.; Gray, A. R. In Organic Synthesis; Wiley: New York, 1943, Vol. II, pp 509-511.
33. Kurzer, F. In Organic Synthesis; Wiley: New York, 1964, Vol. IV, pp 49-50.
34. Joshi, K. C.; Pathak, V. N.; Goyal, M. K. Fluorine Containig Bioactive Heterocycles. Part II. Synthesis of Some New Fluorine Containnig Arylglyoxals, Their Hydrates and 1,5-Disubstituted Hydantoins. J. Heterocycl. Chem. 1981, 18, 1651-1653.
35. Bogdal, D.; Pielichowski, J.; Boron, A. Remarkable Fast Microwave-Assisted N-Alkylation of Phthalimide in Dry Media. Synlett 1996, 9, 873-874.
36. Foces-Foces, C.; Jagerovic, N.; Elguero, J. Crystal Structure of 1,3,5-Triphenyl-2-pyrazoline: A Case of Spontaneous Resolution. Z. Kristallogr. 2001, 216, 240-244.
37. Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-Thioxo-imidazolidin- 4-ones and Imidazolidin-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates. J. Med. Chem. 2005, ASAP Article; DOI: 10.1021/jm050977k.
38. 35S]-GTPγS Binding Assay: Approaches and Applications in Pharmacology. Life Sci. 2003, 74, 489-508.
39. 2 Receptors. Eur. J. Pharmacol. 2004, 495, 43-53.
40. 1 Receptor. J. Med. Chem. 2004, 47, 3048-3057.
41. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide (SR141716A) Interaction with Lys 3.28(192) Is Crucial for Its Inverse Agonism at the Cannabinoid CB1 Receptor. Mol. Pharmacol. 2002, 62, 1274-1287.
42. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997, 267, 727-748.
43. Discover3, 2.98 ed.; Accelrys Inc.: San Diego, CA.
44. Sheldrick, G. Shelxl97: Program for the refinement of molecular crystal structures; University of Göttingen, Germany, 1997.
45. Jonsson, K. O.; Vandevoorde, S.; Lambert, D. M.; Tiger, G.; Fowler, C. J. Effects of Homologues and Analogues of Palmitoylethanolamide upon the Inactivation of the Endocannabinoid Anandamide. Br. J. Pharmacol. 2001, 133, 1263-1275.
46. InsightII; Accelrys Inc. San Diego, CA, 2000.